FBInvestor
Stocks / Halozyme Therapeutics Inc
Institutional Ownership

Halozyme Therapeutics Inc

CUSIP 40637H109COMHALOQ1 2026

13D / 13G Filings
31
Schedule 13D/13G on record
Beneficial Filers
9
Distinct reporting persons
Largest Stake
14.2%
Max % of class reported
Institutional Holders
625
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

31 filings · latest Jul 17, 2025

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Jul 17, 2025Blackrock, Inc.13G/A10.2%12.61MSEC
2May 13, 2025State Street Corporation13G4.9%6.05MSEC
3Apr 28, 2025Blackrock, Inc.13G/A13.1%16.14MSEC
4Nov 12, 2024Artisan Partners Limited Partnership13G/A2.5%3.13MSEC
5Oct 17, 2024State Street Corp13G5.2%6.64MSEC
6Feb 13, 2024Vanguard Group Inc13G/A10.0%13.26MSEC
7Feb 12, 2024Artisan Partners Limited Partnership13G/A5.1%6.69MSEC
8Feb 1, 2024Invesco Ltd.13G/A2.1%2.82MSEC
9Jan 23, 2024Blackrock Inc.13G/A14.1%18.63MSEC
10Jun 9, 2023Vanguard Group Inc13G/A10.3%13.53MSEC

21 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Halozyme Therapeutics Inc.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →
#FundSharesValue
1Blackrock, Inc.13.27M$857.32M
2State Street Corp4.94M$319.13M
3Invesco Ltd.4.01M$259.33M
4Bank Of America Corp /De/2.91M$188.27M
5Boston Partners2.68M$173.43M
6Morgan Stanley2.56M$165.60M
7William Blair Investment Management, LLC2.53M$163.25M
8Geode Capital Management, LLC2.51M$161.98M
9Snyder Capital Management L P2.32M$150.14M
10Dimensional Fund Advisors LP2.08M$134.40M